Patents by Inventor Holger Karsunky

Holger Karsunky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specific for CLL-1
    Patent number: 10723805
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: July 28, 2020
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • Anti-MFI2 antibodies and methods of use
    Patent number: 10428156
    Abstract: Provided are novel anti-MFI2 antibodies and antibody drug conjugates, and methods of using such anti-MFI2 antibodies and antibody drug conjugates to treat cancer.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: October 1, 2019
    Assignee: Abbvie Stemcentrx LLC
    Inventors: Samuel Williams, Laura Saunders, Holger Karsunky, Mandy Boontanrart
  • Antibodies that specifically bind to TIM3
    Patent number: 10301394
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • NOVEL ANTI-EMR2 ANTIBODIES AND METHODS OF USE
    Publication number: 20180327506
    Abstract: Provided are novel anti-EMR2 antibodies and antibody drug conjugates, and methods of using such anti-EMR2 antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: HOLGER KARSUNKY, HANAN FERNANDO, CASEY FRANKLIN, ROBERT A. STULL, DAVID LIU
  • ANTIBODIES SPECIFIC FOR CLL-1
    Publication number: 20180273633
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Application
    Filed: December 22, 2017
    Publication date: September 27, 2018
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180243435
    Abstract: Provided are novel anti-DLL3 antibodies and antibody drug conjugates, and methods of using such anti-DLL3 antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SCOTT J. DYLLA, BRIAN SLINGERLAND, TAE HAN, JOHN PEATTIE, HOLGER KARSUNKY, WADE C. ANDERSON
  • Antibodies specific for CLL-1
    Patent number: 9850314
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: December 26, 2017
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • NOVEL ANTI-MFI2 ANTIBODIES AND METHODS OF USE
    Publication number: 20170320960
    Abstract: Provided are novel anti-MFI2 antibodies and antibody drug conjugates, and methods of using such anti-MFI2 anti-bodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: September 4, 2015
    Publication date: November 9, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SAMUEL WILLIAMS, LAURA SAUNDERS, HOLGER KARSUNKY, MANDY BOONTANRART
  • ANTIBODIES THAT SPECIFICALLY BIND TO TIM3
    Publication number: 20170313783
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Application
    Filed: March 17, 2017
    Publication date: November 2, 2017
    Inventors: Holger KARSUNKY, Ying-Ping Jiang
  • Antibodies that specifically bind to TIM3
    Patent number: 9631026
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 25, 2017
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
    Patent number: 9371390
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: June 21, 2016
    Assignee: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky
  • ANTIBODIES SPECIFIC FOR CLL-1
    Publication number: 20150376290
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • ANTIBODIES THAT BIND MEMBRANE-BOUND IL1RAP
    Publication number: 20150315279
    Abstract: Methods and compositions for binding to the membrane-bound form of IL1 RAP. In some embodiments, the invention provides an isolated antibody that binds the membrane bound fom1 of human IL1 RAP. In some cases, the isolated antibody that binds the membrane-bound form of human IL1 RAP does not bind, or does not substantially bind, the soluble form of human IL1 RAP. For example, in some cases, the isolated antibody that binds the membrane-bound form of human IL1RAP does not bind, or does not substantially bind the soluble form of human IL1RAP that is found in normal human serum. In some cases, the soluble form of human IL1 RAP comprises the sequence GNRCGQ.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 5, 2015
    Inventors: Ying-Ping JIANG, J Yun TSO, Holger KARSUNKY
  • Antibodies specific for CLL-1
    Patent number: 9163090
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: October 20, 2015
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • ANTIBODIES THAT SPECIFICALLY BIND TO TIM3
    Publication number: 20150086574
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Application
    Filed: August 12, 2014
    Publication date: March 26, 2015
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • CYTOKINE RECEPTORS ASSOCIATED WITH MYELOGENOUS HAEMATOLOGICAL PROLIFERATIVE DISORDERS AND USES THEREOF
    Publication number: 20140335103
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Application
    Filed: April 3, 2014
    Publication date: November 13, 2014
    Applicant: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky
  • Antibodies that specifically bind to TIM3
    Patent number: 8841418
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: September 23, 2014
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • MEGAKARYOCYTE PROGENITOR CELLS FOR PRODUCTION OF PLATELETS
    Publication number: 20140205582
    Abstract: Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (MKPs) generated as described result in rapid production of significant numbers of platelets when administered in vivo.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 24, 2014
    Applicant: CELLERANT THERAPEUTICS, INC.
    Inventors: Holger Karsunky, Chanawan Chanaukul, Swapna Pantuganti
  • Compositions and methods for treating haematological proliferative disorders of myeloid origin
    Patent number: 8715619
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: May 6, 2014
    Assignee: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky
  • Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
    Patent number: 8709715
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: April 29, 2014
    Assignee: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky